Epeleuton is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a next-generation synthetic n-3 fatty acid and derivative of an endogenous downstream metabolite of eicosapentaenoic acid (EPA).

Epeleuton is a new chemical entity with additional therapeutic effects compared with other n-3 fatty acids.

Epeleuton’s Phase 2a cardiometabolic and inflammatory data is published in the peer-reviewed Journal of the American Heart Association (JAHA). The paper can be found here.

Epeleuton is currently being investigated in TRIAGE (ClinicalTrials.gov Identifier: NCT04365400), a randomised, double-blind, placebo-controlled, dose finding Phase 2b study which is being conducted in Europe and the United States to assess the efficacy and safety of orally administered Epeleuton in  patients with hypertriglyceridemia and type 2 diabetes.

Patients will receive either Epeleuton (2 or 4 g/day) or placebo for 26 weeks. The primary endpoints are a percentage change in triglycerides from baseline to week 16 and change in HbA1c from baseline to week 26. Results are expected around Q4 2022.

For more information, see: